Biosynthetic pathway is the new chemical process in which bacteria helps to produce and manufacture new class of antibiotics.
Researchers at The University of Manchester's School of Chemistry say their new pathway includes an enzyme, called a carboxylase, which adds CO2 to a precursor molecule producing a highly unusual antibiotic called malonomycin.
Discovery of a New Protein may Pave the Way for Developing Natural Antibiotics
A new protein that likely will advance the search for new natural antibiotics has been discovered by scientists.
Advertisement
‘Patients suffering from various infections could benefit from the new generation antibiotics, which are safe and helpful in fighting the emergence of drug resistant organisms.’
Read More..
Tweet it Now
Read More..
The team says the biosynthetic process used to produce this antibiotic could now possibly lead to the discovery and development of other drugs, helping in the fight against drug-resistant bugs and illnesses in the future.
The work was carried out in collaboration with the University of Cambridge and is being published in Nature Catalysis.
International figures say antibiotic resistance could result in an estimated 10 million deaths every year by 2050, whilst the cost to the global economy could be £66 trillion in lost productivity.
Across Europe alone, an estimated 25,000 people already die each year as a result of hospital infections caused by the antibiotic resistant bacteria such as Escherichia coli (E. coli).
Jason Micklefield, Professor of Chemical Biology at the Manchester Institute of Biotechnology, who led the study, said: "The rapid rise of antibiotic-resistant pathogens is one of the foremost global health concerns of modern times.
"Now, using a combination of bioinformatics, gene editing and in vitro experiments, we have discovered a highly unusual biosynthetic pathway to the antibiotic malonomycin. This could pave the way for a new kind of antibiotic production process."
The team originally became interested in malonomycin because it has a highly unusual chemical structure. It possesses potentially useful antimicrobial activity and has already attracted industrial attention.
However, despite the interest in this antibiotic, very little was known about the biosynthesis of malonomycin, until now.The researchers found that CO2 was introduced into the malonomycin structure, by a carboxylase enzyme that has never been characterised in bacteria before.
Malonomycin carboxylase is most similar to a carboxylase enzyme in human cells which uses vitamin K to add CO2 to proteins in our bodies, triggering essential physiological responses including blood coagulation.
Clinically important anticoagulant drugs, such as warfarin, work by blocking the function of the human vitamin K-dependent carboxylase. Prof Micklefield added: "We were very surprised to find an antibiotic-producing carboxylase enzyme in bacteria that was similar to the human carboxylase responsible for blood clotting.
"We are now optimistic that our findings might lead to the discovery of new antibiotics and may also provide new ways of making antibiotics which are urgently needed to combat emerging drug-resistant pathogens."
Source: Eurekalert
International figures say antibiotic resistance could result in an estimated 10 million deaths every year by 2050, whilst the cost to the global economy could be £66 trillion in lost productivity.
Advertisement
Across Europe alone, an estimated 25,000 people already die each year as a result of hospital infections caused by the antibiotic resistant bacteria such as Escherichia coli (E. coli).
Jason Micklefield, Professor of Chemical Biology at the Manchester Institute of Biotechnology, who led the study, said: "The rapid rise of antibiotic-resistant pathogens is one of the foremost global health concerns of modern times.
"Now, using a combination of bioinformatics, gene editing and in vitro experiments, we have discovered a highly unusual biosynthetic pathway to the antibiotic malonomycin. This could pave the way for a new kind of antibiotic production process."
The team originally became interested in malonomycin because it has a highly unusual chemical structure. It possesses potentially useful antimicrobial activity and has already attracted industrial attention.
However, despite the interest in this antibiotic, very little was known about the biosynthesis of malonomycin, until now.The researchers found that CO2 was introduced into the malonomycin structure, by a carboxylase enzyme that has never been characterised in bacteria before.
Malonomycin carboxylase is most similar to a carboxylase enzyme in human cells which uses vitamin K to add CO2 to proteins in our bodies, triggering essential physiological responses including blood coagulation.
Clinically important anticoagulant drugs, such as warfarin, work by blocking the function of the human vitamin K-dependent carboxylase. Prof Micklefield added: "We were very surprised to find an antibiotic-producing carboxylase enzyme in bacteria that was similar to the human carboxylase responsible for blood clotting.
"We are now optimistic that our findings might lead to the discovery of new antibiotics and may also provide new ways of making antibiotics which are urgently needed to combat emerging drug-resistant pathogens."
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.